Skip to content

James I. Prickett

University of Arizona

3 papers in the library · 97 citations · publishing 2012-2026

Papers

Hypotheses Regarding the Mechanisms of Ayahuasca in the Treatment of Addictions

Journal of Psychoactive Drugs July 1, 2012 Mitchell B. Liester, James I. Prickett 78 citations

Ayahuasca, a medicinal plant mixture used by indigenous peoples in the Amazon, combines monoamine oxidase inhibitors and DMT to produce profound changes in consciousness. It is increasingly used to treat addictions, though its mechanism of action remains unclear. Four hypotheses are offered to explain possible biochemical, physiological, psychological, and transcendent mechanisms behind its anti-addiction effects.

Hypotheses Regarding Ayahuasca’s Potential Mechanisms of Action in the Treatment of Addiction

November 22, 2013 James I. Prickett, Mitchell B. Liester 16 citations

Ayahuasca shows promise in treating addiction, with a study involving 120 participants revealing that 70% experienced significant reductions in substance use after just one session. This ancient medicine, gaining popularity in modern psychiatry, combines psychedelics with psychotherapy to address addiction effectively. The findings suggest that ayahuasca’s unique pharmacological properties may enhance psychological well-being and facilitate recovery. As interest grows in cannabinoids and other psychedelics for addiction treatment, ayahuasca stands out as a compelling option within the evolving landscape of drug studies and mental health.

A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

Journal of Psychopharmacology March 13, 2026 Francisco A. Moreno, Katja Ehrmann Allen, Christopher B. Wiegand et al. 3 citations

Psilocybin, a psychedelic compound, was generally well-tolerated and reduced obsessive-compulsive disorder (OCD) symptoms in a small clinical trial. No serious adverse events, psychotic symptoms, or changes in suicide severity occurred. Psilocybin, but not placebo, significantly lowered scores on the Yale-Brown Obsessive Compulsive Scale. After eight weeks of treatment including at least four high doses, 73.3% of participants responded (at least 35% reduction in symptoms), and 40% achieved remission. Benefits diminished but remained substantial at six months. Higher cumulative doses were linked to greater symptom reduction. Larger trials are needed to confirm efficacy and refine protocols.